Friday, March 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Inovio’s Universal H1N1 Influenza Vaccine Phase I Results

by Global Biodefense Staff
April 18, 2013

InfluenzaInovio Pharmaceuticals, Inc. announced today that its universal H1N1 influenza vaccine, designed to protect against a spectrum of viral strains, generated protective antibody levels comparable to a current FDA-approved seasonal influenza vaccine against a currently circulating influenza strain.

The current FDA-approved trivalent influenza vaccines are designed to protect against only the three strains included in their formulation and are therefore incapable of addressing the inevitable and frequent shift and drift of influenza viral strains that can occur from season to season.

However, scientists have questioned whether an influenza vaccine designed to be broadly protective against multiple, unmatched influenza virus strains could provide the same level of protection as the currently licensed trivalent vaccines that are typically matched to two different influenza A strains and a single influenza B strain.

Inovio’s 100 patient phase I study for the SynCon universal vaccine showed a response rate comparable to that seen in volunteers who received the matched seasonal influenza vaccine.

“We couldn’t be more pleased with the results from this proof-of-principle and dose-finding study of our H1N1 universal influenza vaccine,” said Dr. J. Joseph Kim, Inovio’s President and CEO. “These results further support our mission to develop a universal influenza vaccine capable of providing years of true preemptive protection across subtypes and strains.”

Kim added that the results will also help the company fine-tune dosing for their pandemic avian H5N1 program and support research for the rapidly emerging H7N9 virus.

The results of the SynCon H1N1 Vaccine phase 1 study were presented today at the World Vaccine Congress in Washington, DC, by Dr. Niranjan Sardesai, Inovio’s Chief Operating Officer.

Read more about the study results at Inovio: Broadly targeted SynCon H1N1 vaccine induces protective antibodies comparable to current seasonal vaccine against currently circulating influenza strain.

Tags: Avian InfluenzaH1N1InfluenzaUniversal Flu VaccineVaccines

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC